Protalix BioTherapeutics, Inc. (PLX) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 31.39M USD | Liabilities, Current |
| Cash and equivalents | 27.42M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 16.50M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 32.29M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $31.39M | $27.42M | (m) | $16.50M | $32.29M | (m) |
| 2026-03-31 | (m) | $27.39M | $41.00M | (m) | $2.94M | $30.47M | (m) |
| 2025-12-31 | (m) | $26.52M | $14.68M | (m) | $8.84M | $25.73M | (m) |
| 2025-09-30 | (m) | $21.95M | $13.65M | (m) | $14.43M | $21.25M | (m) |
| 2025-06-30 | (m) | $24.09M | $17.89M | (m) | $9.44M | $21.13M | (m) |
| 2025-03-31 | (m) | $24.32M | $19.46M | (m) | $4.67M | $19.51M | (m) |
| 2024-12-31 | (m) | $25.62M | $19.76M | (m) | $2.91M | $21.24M | (m) |
| 2024-09-30 | (m) | $24.22M | $27.41M | (m) | $2.19M | $17.20M | (m) |
| 2024-06-30 | (m) | $57.97M | $23.40M | (m) | $10.13M | $20.72M | (m) |
| 2024-03-31 | (m) | $54.83M | $27.21M | (m) | $3.76M | $22.35M | (m) |
| 2023-12-31 | (m) | $45.53M | $23.63M | (m) | $5.27M | $19.05M | (m) |
| 2023-09-30 | (m) | $43.36M | $20.41M | (m) | $8.94M | $21.58M | (m) |
| 2023-06-30 | (m) | $23.11M | $48.18M | (m) | $4.05M | $19.64M | (m) |
| 2023-03-31 | (m) | $31.52M | $33.04M | (m) | $1.30M | $20.30M | (m) |
| 2022-12-31 | (m) | $32.43M | $17.11M | (m) | $4.59M | $16.80M | (m) |
| 2022-09-30 | (m) | $34.30M | $10.72M | (m) | $8.65M | $14.56M | (m) |
| 2022-06-30 | (m) | $30.96M | $12.49M | (m) | $2.02M | $16.51M | (m) |
| 2022-03-31 | (m) | $35.33M | $16.89M | (m) | $5.91M | $16.59M | (m) |
| 2021-12-31 | (m) | $33.18M | $38.98M | (m) | $3.44M | $17.95M | (m) |
| 2021-09-30 | (m) | $42.76M | $10.64M | (m) | $5.56M | $14.73M | (m) |
| 2021-06-30 | (m) | $96.25M | $33.88M | (m) | $2.33M | $13.64M | (m) |
| 2021-03-31 | (m) | $80.86M | $19.83M | (m) | $4.60M | $13.91M | (m) |
| 2020-12-31 | (m) | $86.47M | $18.27M | (m) | $2.00M | $13.08M | (m) |
| 2020-09-30 | (m) | $43.90M | $13.53M | (m) | $3.15M | $13.28M | (m) |
| 2020-06-30 | (m) | $42.41M | $4.84M | (m) | $5.26M | $11.06M | (m) |
| 2020-03-31 | (m) | $47.63M | $14.17M | (m) | $8.88M | $9.49M | (m) |
| 2019-12-31 | (m) | $40.17M | $17.79M | (m) | $4.70M | $8.15M | (m) |
| 2019-09-30 | (m) | $33.32M | $21.44M | (m) | $8.72M | $7.53M | (m) |
| 2019-06-30 | (m) | $25.99M | $25.10M | (m) | $7.26M | $7.00M | (m) |
| 2019-03-31 | (m) | $27.04M | $30.36M | (m) | $8.56M | $6.71M | (m) |
| 2018-12-31 | (m) | $25.35M | $37.81M | (m) | $4.73M | $8.57M | (m) |
| 2018-09-30 | (m) | $14.55M | $41.87M | (m) | $4.89M | $7.96M | (m) |
| 2018-06-30 | (m) | $15.07M | $28.33M | (m) | $5.25M | $6.98M | (m) |
| 2018-03-31 | (m) | $21.50M | $41.32M | (m) | $4.76M | $7.02M | (m) |
| 2017-12-31 | (m) | $22.75M | $51.16M | (m) | $1.72M | $7.83M | (m) |
| 2017-09-30 | (m) | $26.59M | $33.48M | (m) | $7.29M | $7.48M | (m) |
| 2017-06-30 | (m) | $19.12M | $34.53M | (m) | $3.00M | $7.06M | (m) |
| 2017-03-31 | (m) | $20.29M | $48.02M | (m) | $2.74M | $7.10M | (m) |
| 2016-12-31 | (m) | $66.21M | $63.28M | (m) | $693.00K | $5.25M | (m) |
| 2016-09-30 | (m) | $10.33M | $51.32M | (m) | $2.10M | $4.86M | (m) |
| 2016-06-30 | (m) | $11.46M | $54.63M | (m) | $1.49M | $6.07M | (m) |
| 2016-03-31 | (m) | $9.28M | $66.67M | (m) | (m) | $5.74M | (m) |
| 2015-12-31 | (m) | $11.23M | $76.37M | (m) | (m) | $5.77M | (m) |
| 2015-09-30 | (m) | $22.85M | $34.25M | (m) | $4.57M | $6.34M | (m) |
| 2015-06-30 | (m) | $25.52M | $43.24M | (m) | $1.94M | $6.37M | (m) |
| 2015-03-31 | (m) | $26.55M | $47.96M | (m) | $1.82M | $6.88M | (m) |
| 2014-12-31 | (m) | $26.21M | $54.77M | (m) | $1.88M | $6.67M | (m) |
| 2014-09-30 | (m) | $24.38M | $60.32M | (m) | $1.99M | $6.83M | (m) |
| 2014-06-30 | (m) | $27.18M | $71.14M | (m) | $2.10M | $7.13M | (m) |
| 2014-03-31 | (m) | $26.78M | $77.69M | (m) | $1.74M | $6.53M | (m) |
| 2013-12-31 | (m) | $26.70M | $86.40M | (m) | $2.09M | $7.96M | (m) |
| 2013-09-30 | (m) | $25.23M | $91.40M | (m) | $2.05M | $7.58M | (m) |
| 2013-06-30 | (m) | $26.63M | $33.13M | (m) | $2.03M | $7.19M | (m) |
| 2013-03-31 | (m) | $24.41M | $41.87M | (m) | $1.70M | $5.77M | (m) |
| 2012-12-31 | (m) | $25.75M | $52.03M | (m) | $1.41M | $4.04M | (m) |
| 2012-09-30 | (m) | $20.43M | $50.22M | (m) | $4.03M | $2.06M | (m) |
| 2012-06-30 | (m) | $21.33M | $59.28M | (m) | $1.54M | $1.03M | (m) |
| 2012-03-31 | (m) | $17.72M | $45.60M | (m) | $815.00K | $263.00K | (m) |
| 2011-12-31 | (m) | $18.69M | $27.00M | (m) | $1.37M | $279.00K | (m) |
| 2011-09-30 | (m) | $18.31M | $34.56M | (m) | $2.28M | $427.00K | (m) |
| 2011-06-30 | (m) | $20.28M | $44.05M | (m) | $1.72M | $537.00K | (m) |
| 2011-03-31 | (m) | (m) | $50.23M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $18.90M | $35.90M | (m) | $7.01M | $1.19M | (m) |
| 2010-09-30 | (m) | (m) | $44.40M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $54.96M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $81.27M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $42.60M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |